Clinical Trials Logo

Renal Anemia clinical trials

View clinical trials related to Renal Anemia.

Filter by:

NCT ID: NCT01306409 Completed - Renal Anemia Clinical Trials

Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)

Start date: January 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to gain information on reticulocyte neocytolysis in patients treated with ESA with regard to different types of ESA.

NCT ID: NCT00456053 Completed - Renal Anemia Clinical Trials

A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.

NCT ID: NCT00322413 Completed - Clinical trials for End Stage Renal Disease

Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial

Start date: January 1997
Phase: Phase 3
Study type: Interventional

The two epoetins, Epoetin alfa, a well established drug to treat renal anemia and Epoetin Omega, that differs from Epoetin alfa in the sugar moiety of the molecule were compared in regard of efficacy and safety to treat end stage renal disease anemia. Study hypothesis was that Epoetin Omega is non-inferior to Epoetin alfa in correcting renal anemia in dialysis patients. A 12-weeks randomized comparative efficacy study was performed including 77 end stage renal disease patients (epoetin omega:n=39, epoetin alfa: n=38). In the intent-to-treat analysis, average weekly difference in hemoglobin versus baseline value was higher in omega-treated patients: 1.94+-0.81 vs. 1.23+-0.62 g/dl. The unadjusted and adjusted omega-alfa differences were 0.71 g/dl (95%CI 0.38 to 1.04; p<0.001) and 0.78 g/dl (0.49 to 1.08;p<0.001), respectively. Average weekly epoetin dose was lower in the omega group: 87+-25 vs. 108+-21 IU/kg. The unadjusted and adjusted omega-alfa differences were -21IU/kg (-32 to -11; p<0.001) and -24IU/kg (-35 to -13; p<0.001), respectively. Epoetins were comparably well tolerated. In dialysis patients, subcutaneous epoetin omega apparently provides a greater anti-anemic effect per administered dose (IU) than epoetin alfa.

NCT ID: NCT00298441 Completed - Hemodialysis Clinical Trials

Efficacy of Intravenous Iron Administration in Hemodialysis Patients

Start date: June 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether the frequency of intravenous iron administration has an effect on anemia correction and oxidative stress formation in hemodialysis patients.